Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
65.87
+3.31 (5.29%)
At close: May 27, 2025, 4:00 PM
65.96
+0.09 (0.14%)
After-hours: May 27, 2025, 7:59 PM EDT
Tempus AI Revenue
Tempus AI had revenue of $255.74M in the quarter ending March 31, 2025, with 75.38% growth. This brings the company's revenue in the last twelve months to $803.32M, up 42.93% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$803.32M
Revenue Growth
+42.93%
P/S Ratio
12.02
Revenue / Employee
$334,715
Employees
2,400
Market Cap
11.40B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TEM News
- 2 days ago - Tempus AI: Firing On All Cylinders - Seeking Alpha
- 4 days ago - These Investors Search for ‘Extreme Winners.' Why Aurora, BYD, Tempus AI Make the Cut. - Barrons
- 5 days ago - Tempus AI: I Believe In The Company's Cause - Seeking Alpha
- 6 days ago - Tempus to Present at the William Blair 45th Annual Growth Stock Conference - Business Wire
- 7 days ago - Tempus: Is This Ultra-Fast-Growing Company A Good Investment? - Seeking Alpha
- 7 days ago - Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - Business Wire
- 13 days ago - Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline - Business Wire
- 13 days ago - Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle - GlobeNewsWire